Cutter Law, P.C., along with Chuck and Gena Norris, announce the filing of a gadolinium lawsuit against McKesson Corporation and other defendants, alleging the companies are responsible for a serious, debilitating condition known as Gadolinium Deposition Disease. We further allege the companies failed to adequately warn about the risk, putting patients at risk of life-long complications. Gena and Chuck Norris are represented by Cutter Law attorney Todd Walburg. The gadolinium lawsuit was filed on November 2, 2017.
Gadolinium Deposition Disease is an incurable disease linked to the use of Gadolinium-Based Contrast Agents during MRI procedures. Although another gadolinium-related condition-nephrogenic systemic fibrosis-is linked to patients who have impaired kidney function, Gadolinium Deposition Disease affects patients who have normal or near normal kidney function.
Patients with Gadolinium Deposition Disease (GDD), experience persistent symptoms that begin within hours to months after the contrast agent has been administered. Over the past 18 years, considerable scientific research has shown that gadolinium has a toxic effect on animals and humans, yet warnings to patients about that toxic effect have been inadequate.
Before undergoing her MRI, Gena Norris, Chuck Norris’ wife,was a healthy, athletic woman with normal kidney function. Over an eight-day period, she underwent three MRIs, all three of which involved the use of MultiHance and ProHance, Gadolinium-Based Contrast Agents. Immediately following the scans, Gena felt sick and three days later was rushed to the hospital with burning in her abdomen.
“After almost five years of dealing with this condition, which has only recently become known as Gadolinium Deposition Disease, it is difficult for me to recount this ordeal,” Gena Norris wrote to the FDA Medical Imaging Drugs Advisory Committee Meeting (read by Cutter Law Attorney Todd Walburg). “It brings back horrific memories that I have tried to block out, but some things I cannot forget.”
Among the symptoms, Gena suffered were burning pain throughout her body, violent shaking, low body temperature, muscle cramps, kidney damage, weakness, fatigue, and confusion.
Following repeated trips to the hospital, visits with a urologist, severe brain fog, and burning sensations, Gena’s health continued deteriorating. She was tested for cancer and a variety of health problems, but no diagnosis was made. It wasn’t until a trip to the TEDA International Cardiovascular Hospital in Tianjin, China, that Gena learned her Gadolinium levels were drastically high and her kidneys were damaged. She currently undergoes regular stem cell therapy and constantly deals with the effects of having received a Gadolinium-Based Contrast Agent for her three MRIs.
In all, Gena and Chuck spent more than $2 million to diagnose and treat Gena’s Gadolinium Deposition Disease.
Chuck and Gena Norris allege Gena’s development of Gadolinium Deposition Disease was the direct result of her exposure to gadolinium. Furthermore, they allege the makers and distributors of Gadolinium-Based Contrast Agents knew or should have known about the risks of GDD but failed to warn patients or healthcare providers of that risk.
Manufacturers of Gadolinium-Based Contrast Agents convinced the medical community and patients that the only people at risk of an adverse reaction are patients with abnormal kidney function when in reality, even patients with normal kidney function are at risk. Because doctors are not aware of the potential for a reaction in patients with normal kidney function, such patients are often misdiagnosed delaying their ability to get appropriate medical attention and putting them at risk of further medical problems and expenses.
The lawsuit is case number CGC-17-562228, in Superior Court for the State of California, County of San Francisco.
Cutter Law, P.C., represents plaintiffs who have filed lawsuits in both state and federal courts against GBCA manufacturers. Those lawsuits are in the early stages and more gadolinium lawsuits are anticipated.